Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Unresectable Endometrial Carcinoma: early-phase trial registry

1 of 1 indexed Unresectable Endometrial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Unresectable Endometrial Carcinoma: 1 US clinical trial tracked, 1 recruiting.

Unresectable Endometrial Carcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Aaron Wolfson, running 1 of these trials.

Enrollment posture brief

Registry condition unresectable-endometrial-carcinoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Unresectable Endometrial (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Unresectable Endometrial Carcinoma

Unresectable Endometrial Carcinoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Unresectable Endometrial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Unresectable Endometrial Carcinoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Aaron Wolfson 1 trials

Named interventions

Most-linked intervention names on Unresectable Endometrial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Lenvatinib Drug
1 trials
Hypofractionated External Beam Radiation Therapy Radiation
1 trials
Pembrolizumab Drug
1 trials

US sites by state

Facility locations filed on Unresectable Endometrial Carcinoma trials. A trial with sites in several states counts in each.

Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Unresectable Endometrial Carcinoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Unresectable Endometrial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Aaron Wolfson sponsors the most Unresectable Endometrial Carcinoma trials on record, review their full trial history before evaluating a specific study. See Aaron Wolfson's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unresectable Endometrial Carcinoma condition card totals 1 registered trials; most-linked intervention Lenvatinib; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.